Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
Cocrystal Pharma, Inc. (NASDAQ: COCP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs [Yahoo! Finance]
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Cocrystal Pharma, Inc. (NASDAQ: COCP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.